Tarsus Pharmaceuticals appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026. She has been key in launching XDEMVY, a treatment for Demodex blepharitis, and will now lead commercial strategy to expand its market and advance Tarsus' pipeline, including treatments for retinal diseases and ocular conditions. Clase brings over 25 years of biopharma experience and aims to grow XDEMVY's sales potential beyond $2 billion while preparing for future product launches.
Tarsus Pharmaceuticals' leadership update is given context by Pluang's health sector market data as of Oct 28, 2026 19:11 WIB. Among 150 priced US health stocks tradable on Pluang, 42 rose and 97 fell today. Notable movers include IMVT at USD 29.40 with a 1-day change of +1.80%, MMED at USD 18.60 with -1.74%, and MRNA at USD 204.53 with -1.65% and a Pluang order activity skewed 80% Sell / 20% Buy, with a typical hold time of 58 days.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
